Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105

The FDA approval of bevacizumab (Avastin(®), Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for ant...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Immunother
Hlavní autoři: Wood, Laurence M., Pan, Zhen-Kun, Guirnalda, Patrick, Tsai, Peter, Seavey, Matthew, Paterson, Yvonne
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2011
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4438988/
https://ncbi.nlm.nih.gov/pubmed/21431419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1002-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky